What is the role of pyridopyrimidine in breast cancer?
Best insight from top research papers
Pyridopyrimidine compounds have been developed as potential anticancer agents, including for breast cancer treatment. These compounds have been derived from pyridine and pyrimidines fusion or from possible isomeric forms of pyridopyrimidine derivatives. They have shown biological applications such as growth inhibition by cell cycle arrest, apoptosis, inhibition of angiogenesis, disruption of cell migration, and mutation. Pyridopyrimidine compounds have been found to target receptors and enzymes involved in cancer, including dihydrofolate reductase, tyrosine kinase, cyclin-dependent kinase-4 and 6, and fibroblast growth factor receptor. They have also been shown to have an impact on immune checkpoints, tumor-infiltrating immune cells, and cytokine levels, suggesting potential implications for immunotherapy in breast cancer. Studies have focused on the synthesis and testing of pyridopyrimidine compounds for their anticancer activity, highlighting their potential as a therapeutic approach for breast cancer treatment.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| The provided paper does not specifically mention the role of pyridopyrimidine in breast cancer. | |
| The provided paper does not specifically mention the role of pyridopyrimidine in breast cancer. The paper focuses on the anticancer functions of pyridine heterocycles in general, including their ability to inhibit various targets in cancer therapy. | |
04 Jan 2023 | The provided paper does not specifically mention the role of pyridopyrimidine in breast cancer. The paper discusses the role of pyridine and pyrimidine scaffolds in the development of novel anticancer agents, but it does not provide specific information about pyridopyrimidine in breast cancer. |
| The provided paper does not specifically mention the role of pyridopyrimidine in breast cancer. | |
| The provided paper does not specifically mention the role of pyridopyrimidine in breast cancer. |
Related Questions
How was digoxin used in treatment of breast cancer?5 answersDigoxin, a cardiac glycoside, has shown promise in breast cancer treatment. Studies reveal that digoxin induces ERα degradation, inhibits 17β-estradiol signaling, blocks the cell cycle in the G2 phase, and triggers apoptosis in breast cancer cells, both primary and metastatic. Additionally, digoxin has been found to inhibit the growth of breast cancer cells by inducing mitochondria-dependent apoptosis, reducing Bcl-2 expression, and increasing Bax levels. Furthermore, digoxin and its synthetic analog MonoD have demonstrated cytotoxic effects on breast cancer cells, including triple-negative breast cancer, by increasing the G0/G1 cell cycle phase, decreasing cell viability, inhibiting migration, and inducing apoptosis through the nuclear factor kappa B pathway. These findings highlight the potential of digoxin in the treatment of various types of breast cancer.
What are the potential therapeutic applications of triazolopyrimidine compounds?5 answersTriazolopyrimidine compounds exhibit a wide array of potential therapeutic applications. These include anti-Alzheimer, antidiabetes, anticancer, antimicrobial, antituberculosis, antiviral, antimalarial, anti-inflammatory, anti-parkinsonism, and glaucoma treatment activities. Moreover, they have shown promise as anticancer agents targeting various cancer-associated pathways. Triazolopyrimidines have been explored for their pharmacological activities such as anticancer, antimicrobial, anti-tubercular, and CB2 cannabinoid agonist properties, indicating their potential in medicinal chemistry. Additionally, these compounds can modulate adenosine receptors and are implicated in the treatment of diseases like cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. The diverse biological activities and pharmacological potential of triazolopyrimidines make them promising candidates for various therapeutic interventions.
What are the drug targets of breast cancer?4 answersBreast cancer has several drug targets that have been identified through research. These targets include HER2, TROP-2, cyclin D-dependent kinases CDK4 and CDK6, the PI3K/AKT/mTOR pathway, the insulin/IGF1R pathway, the EGFR/HER family, the JAK/STAT pathway, poly(ADP-ribose) polymerases (PARP), Src kinases, histone modification enzymes, activated growth factor receptors, androgen receptors, breast cancer stem cells, matrix metalloproteinases, and immune checkpoint proteins. In addition to these targets, the protein kinase With No Lysine (WNK) has also been identified as a potential drug target for triple negative breast cancer (TNBC). These targets have been explored for the development of novel therapeutic strategies and some drugs targeting these molecules/pathways are already FDA-approved or being tested in clinical trials. The identification of these targets provides opportunities for the development of more efficient treatments for breast cancer, particularly for metastatic and triple negative breast cancer.
Chemotherapy for breast cancer?5 answersChemotherapy is an important component of breast cancer therapy and has shown benefit in both early and advanced disease. Anthracyclines and taxanes are commonly used drugs in breast cancer treatment. The use of cytotoxic chemotherapy in breast cancer has made significant progress in the last decade, with several studies identifying clear survival benefits for newer therapies. However, the optimal approach for each patient cannot be determined solely based on literature reviews or algorithms, as treatment choices are often based on individual or collective experience. Personalized therapies based on the molecular characteristics of the tumor could improve the risk-benefit ratio of current therapies. Overall, chemotherapy has contributed to improved survival for breast cancer patients, but the decision of when to administer cytotoxic therapy and which agents to use remains a complex challenge.
Does temsirolimus have a role in the treatment of breast cancer?5 answersTemsirolimus, an analog of rapamycin, has been studied for its potential role in the treatment of breast cancer. However, the available evidence suggests that single-agent temsirolimus has minimal activity in heavily pretreated breast cancer patients. While preclinical models have shown that activating mutations of the PIK3CA gene, which is associated with estrogen receptor (ER) positivity, may be sensitive to mTOR inhibitors, no association was found between PIK3CA mutation and clinical benefit in this study. Additionally, temsirolimus has been studied in combination with chemotherapy in various cancers, including breast cancer, with response rates ranging from 10 to 20%. Therefore, while temsirolimus shows promise as a new drug, further research is needed to determine its efficacy and optimal use in the treatment of breast cancer.
Chemotherapy drugs for breast cancer?3 answersChemotherapy drugs commonly used for breast cancer treatment include methotrexate, 5-fluorouracil (5-FU), cyclophosphamide, anthracyclines, taxanes, trastuzumab, tamoxifen, and aromatase inhibitors. These drugs inhibit breast cancer progression through various mechanisms. Other chemotherapeutic agents like doxorubicin, cisplatin, and camptothecin are also used in breast cancer treatment. Additionally, newer drugs such as capecitabine and oxaliplatin have been recommended for adjuvant treatment of stage III colon cancer after surgery. Non-steroidal anti-inflammatory drugs (NSAIDs), metformin, and statins have also shown potential in the primary chemoprevention of breast cancer. These drugs could be used in combination with hormonal drugs like selective estrogen receptor modulators and aromatase inhibitors due to their alternative mechanisms of action.